Aker BioMarine will release the first quarter 2023 results on Friday 28 April
2023 at 07:00 CET. 

At 09:00 CET on the same day, the management will host a webcast to present the
results. Following a presentation, there will be a Q&A session where written
questions can be submitted to ir@akerbiomarine.com. 

The webcasted presentation will be in English. To join, please use the link that
will be available at www.akerbiomarine.com/investor. 

A replay of the presentation and Q&A session will be made available soon after
the presentation at the same web page.

For further information, please contact 
Katrine Klaveness, CFO
Mobile: +47 991 58 915
Email:  Katrine.Klaveness@akerbiomarine.com


About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for pharma, consumer health and
wellness as well as animal nutrition. The company has a strong position in its
industry and is the world's leading supplier of krill, the natural, powerful and
health promoting source of nutrients from the pristine waters of Antarctica.
Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is
available at www.akerbiomarine.com.